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Abstract
The Background: Ribonuclease L (RNASEL), encoding the 29-59-oligoadenylate (2-5A)-dependent RNase L, is a key enzyme in
the interferon induced antiviral and anti-proliferate pathway. Mutations in RNASEL segregate with the disease in prostate
cancer families and specific genotypes are associated with an increased risk of prostate cancer. Infection by human
papillomavirus (HPV) is the major risk factor for uterine cervix cancer and for a subset of head and neck squamous cell
carcinomas (HNSCC). HPV, Epstein Barr virus (EBV) and sequences from mouse mammary tumor virus (MMTV) have been
detected in breast tumors, and the presence of integrated SV40 T/t antigen in breast carcinomas correlates with an
aggressive phenotype and poor prognosis. A genetic predisposition could explain why some viral infections persist and
induce cancer, while others disappear spontaneously. This points at RNASEL as a strong susceptibility gene.
Methodology/Principal Findings: To evaluate the implication of an abnormal activity of RNase L in the onset and
development of viral induced cancers, the study was initiated by searching for germline mutations in patients diagnosed
with uterine cervix cancer. The rationale behind is that close to 100% of the cervix cancer patients have a persistent HPV
infection, and if a defective RNase L were responsible for the lack of ability to clear the HPV infection, we would expect to
find a wide spectrum of mutations in these patients, leading to a decreased RNase L activity. The HPV genotype was
established in tumor DNA from 42 patients diagnosed with carcinoma of the uterine cervix and somatic tissue from these
patients was analyzed for mutations by direct sequencing of all coding and regulatory regions of RNASEL. Fifteen mutations,
including still uncharacterized, were identified. The genotype frequencies of selected single nucleotide polymorphisms
(SNPs) established in the cervix cancer patients were compared between 382 patients with head and neck squamous cell
carcinomas (HNSCC), 199 patients with primary unilateral breast cancer and 502 healthy Danish control individuals. We
found that the genotype frequencies of only one of the 15 mutations, the yet uncharacterized 59UTR mutation rs3738579
differed significantly between cancer patients and control individuals (P-value: 4.43610
25).
Conclusion/Significance: In conclusion, we have discovered an increased risk, a heterozygous advantage and thereby a
protective effect linked to the RNASEL SNP rs3738579. This effect is found for patients diagnosed with carcinoma of the
uterine cervix, HNSCC, and breast cancer thus pointing at RNASEL as a general marker for cancer risk and not restricted to
familial prostate cancer.
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Introduction
Ribonuclease L (RNASEL) encoding the versatile endoribonu-
clease RNase L is a key enzyme in the interferon induced antiviral
and anti-proliferate pathway, involved in cellular viral defense,
single-stranded RNA cleavage and tumor suppressor activities as
stress mediated apoptosis, cell proliferation and regulation of
protein synthesis [1–5].
RNase L is activated in response to viral infection and the
presence of virally encoded dsRNA mobilizes the type I interferons
(IFN), which activate a family of 29-59 oligoadenylate synthetases
(OAS) [6,7]. With ATP as substrate these enzymes produce
59-phosphorylated 29-59 linked oligoadenylates (2-5A), which
activate RNase L by binding to the ankyrin repeats and inducing
dimerization, essential for the endonuclease activity of RNase L
[8].
Human RNase L comprises 741 amino acids, and three
different domains, a nine ankyrin repeat in the N-terminal, a
kinase-like and an RNase domain in the C-terminal part. The
ankyrin repeats are known to be involved in protein/protein
interactions, but the RNase L ankyrin repeats (2 to 4) bind the 2-
5A molecule, which initiates the conformational change of RNase
L leading to dimerization and thereby activation of the enzyme
[9,10]. Based upon sequence comparison it is predicted that
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2492RNase L should have protein kinase activity, but it has not been
experimentally verified [11]. However, two missense mutations
(R462Q and K392R) located in the protein kinase region have been
shown to affect the enzyme dimerization and activity [12]. R462Q is
a frequent and well-characterized mutation and homozygosity for
the rareallelereducestheactivity of RNase L by3 fold[13].K392R,
located in the protein kinase-like region II and implicated in binding
ofATPinkinases,preventsthedimerization ofRNaseLandthereby
the activation of the enzyme [12]. The kinase-like and ribonuclease
domains are related to those found in IRE 1, a transmembrane
serine/threonine protein kinase receptor involved in the response to
unfolded proteins in the ER [14].
RNASEL islocatedwithin the hereditaryprostate cancer 1 (HPC1)
region at 1q25.3. Chromosomal gain comprising this region has
been found as a frequent event in uterine cervix cancer [15] and
HNSCC [16] and amplification of the entire chromosome arm 1q is
considered an early event in breast carcinogenesis [17].
Germline mutations in RNASEL segregate with the disease in
prostate cancer families with linkage to the HPC1 region at 1q25.3
[18]. The majority of missense mutations are found within exon 2
encoding the ankyrin repeats and part of the kinase-like domain.
Cells from carriers of M1I and E265X showed half the normal
activity of RNase L and the normal allele was lost in tumor cells
from patients heterozygous for these muations [18]. E265X
terminates translation within the 2-5A binding domain of RNase
L, a similar mutation has been shown to eliminate 2-5A binding in
mice [1]. The mutation was originally identified in four brothers,
three of which suffered from aggressive prostate cancer [18].
Carriers of E265X develop prostate cancer on an average of 11
years before non-carriers from the same families [19]. A founder
mutation 471delAAAG, resulting in a truncated protein, is
associated with prostate cancer in Ashkenazi Jews [20]. A number
of missense mutations are found in hereditary prostate cancer
(HPC) families as: G59S, I97L, I220V, S406F, R462Q, Y529C
and D541E, no mis- or nonsense mutations have been found in the
ribonuclease domain. The mutations G59S, I97L, I220V, G296V,
S322F, Y529C and D541E showed normal level of RNase L when
measured in a mouse RNase L
2/2 cell line [3].
Due to the tumor suppressor activities of RNASEL it is suggested
that RNase L directly or indirectly suppress one or more steps in the
prostate tumorigenesis or metastasis formation [21]. Germline
mutations in RNASEL have been intensively studied in sporadic
and familial prostate cancer but the results are contradictive.
Recently, a comprehensive meta-analysis comprising the mutations
D541E, R462Q and E265X concluded that the genotype E541
increased the risk of developing prostate cancer for Caucasian men,
regardless of a family history of the disease [21]. In contrast, E541
was found to increase the risk of prostate cancer in Japanese families
withmultipleaffectedmembers[22].Amarginaleffecthasbeenseen
for E541 in the Swedish population but studies on other populations
could not confirm these results [13,19,23,24].
R462Q is located in the kinase-like domain, and the R462Q
variant is capable of binding 2-5A, with a reduced ability to
dimerize, a configuration necessary for the enzymatic activity [3].
The catalytic activity of the mutant enzyme is decreased three fold
when compared to the wild type RNase L, and it is no longer
capable of inducing apoptosis [13]. Males heterozygous for
R462Q have a 1.5-fold elevated risk, and homozygous men
double the risk of developing prostate cancer, suggesting R462Q
to be a predictive marker for the malignancy [13].
Association between the R462Q carriers and risk of developing
prostate cancer seems to depend highly on ethnicity. Mutations in
RNASEL are found at a very low rate in the German and Swedish
population, and no significant association was found between
R462Q and risk of prostate cancer [23,25]. Homozygosity for
462Q was significantly more frequent in Finnish prostate cancer
families than in controls, and in Euro-Americans with a family
history of prostate cancer, R462Q was inversely associated with
low grade and low stage disease [19,26]. A significant association
was found between R462Q and an increased risk of early-stage
and low-grade disease in Euro-Americans patients with no family
history [26]. In Afro-Americans R462Q was associated with a
positive family history and high-grade tumors [26].
Patients with a familial pancreatic cancer, which are homozy-
gous for 462Q, presented a more aggressive disease with a high
risk of developing metastasis [27] and the genotype is associated
with age of onset of hereditary non-polyposis colon cancer
(HNPCC) [28]. No association was found between breast cancer
risk and any R462Q genotype [29]. Recently, a strong link was
established between impaired RNase L activity and infection by a
novel gammaretrovirus [30]. cDNA from prostate cancer patients
with different genotypes for R462Q, were used to screen an
oligonucleotide array containing the most conserved sequences
from all known viruses. Forty percent of the patients homozygous
for 462Q were found to be infected by the xenotrophic murine
leukemia virus (XMLV), whereas only 1.5% of patients being
heterozygous and homozygous (RR) carried the virus. Cells,
homozygous for Q have a decreased RNase L catalytic activity
and loose the ability to go into apoptosis, strongly indicating that
RNase L plays a role in clearing viral infection.
It is estimated that 80%of alladults will acquirean HPV infection
atsomepointoftheirlife.Worldwide,500,000womenarediagnosed
with cervical cancer and the prevalence of a genital HPV infection is
estimated to be 326 million among adult women [31].
HNSCC is the sixth most frequent cancer form with 650,000
new incidents and 350,000 deaths per year worldwide [31]. The
major risk factors are tobacco and alcohol consumption, body
mass and HPV infection, the latter is especially associated with
oropharyngeal cancer [32].
Breast Cancer is the second most frequent cancer in the world
and the most common in women with more than 1 million new
cases and more than 411,000 deaths per year [33]. The major risk
factors are age, early menarche, late age of first pregnancy, late
menopause, hormone exposure, and lack of exercise [34,35].
HPV is the major risk factor for uterine cervical cancer [36] and
responsible for approximately one fourth of the HNSCC cases
[37]. The highest prevalence is found for squamous cell
carcinomas (SCC) located at the tonsils, oropharynx, oral and
larynx [38]. The HPV strains 16 and 18 are associated with 99.7%
of all cervical cancers [39] and HPV-16 with 86.7% of
oropharyngeal SSC, 68.2% of oral SSC and 69.2% of laryngeal
SSC [37]. HPV-16 and 18 are among the high-risk viruses,
encoding the oncoproteins E6 and E7, which are capable of
silencing p53 and pRb, respectively. Thereby, they are omitting
important cell cycle checkpoints [40,41].
Di Lonardo et al. were the first to identify HPV-16 DNA in
breast carcinomas [42]. Worldwide studies show a considerable
geographic difference in the prevalence of HPV in breast
carcinomas varying from 0–86%, described in [43]. In addition,
the mouse mammary tumor virus (MMTV) has been found in
breast tumors, and insertion sites in the human genome affects
genes, which are part of gene families and pathways involved in
breast carcinogenesis [44]. Likewise, Epstein Barr virus (EBV),
human herpes virus-8 (HHV-8) and bovine leukemia virus (BLV)
have been detected in breast tumors, reviewed in [45].
The majority of viral infections are cleared by the immune
system, and a genetic predisposition could explain why the
infection persists and induce cancer in some individuals.
RNASEL Predicts Cancer Risk
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combination of genotypes (haplotype) across RNASEL, which could
prove to be a marker for the individual risk of acquiring a persistent
HPV infection, thereby an increasing risk of developing especially
uterine cervix and head and neck cancer. The promoter region and
the 59 and 39 UTR were included in the search for new mutations. A
yet uncharacterized 59UTR mutation, being in linkage disequilib-
rium (LD) with well characterized missense mutations in exon 2,
proved to be a statistical strong marker for increased risk and
heterozygous protection from all three cancer forms.
Results and Discussion
Mutational spectrum of RNASEL in cervical carcinomas
As viral infection is implicated in close to 100% of all uterine
cervix cancer cases, we hypothesized that if a defective RNase L is
responsible for the lack of ability to clear a viral infection, patients
with cervix cancer would carry a wide spectrum of mutations
affecting the activity or expression level of RNase L. Therefore,
leukocyte DNA from 42 patients diagnosed with uterine cervix
cancer were screened for mutations by direct sequencing of both
DNA strands of all coding and regulatory regions of RNASEL. The
HPV genotype was established on DNA isolated from each tumor.
We identified 15 different mutations: four non-synonymous
(I97L, F364L, R462Q and D541E), one nonsense (E265X), one
synonymous (K724K) and nine in un-translated regions (Figure 1).
The mutations of I97L and E265X are positioned in the ankyrin
repeat three and seven, respectively, and F364L, R462Q and
D541E are part of the kinase-like domain. No mis- or nonsense
mutations were found in the RNase domain in consistency with
previous reports (reviewed in [46,47]). One highly polymorphic T
to C mutation (rs3738579) was present in 59UTR of exon 2, 95 bp
upstream from the translation initiation codon. The intron
mutations comprised rs12742422, an A.G, 59 bp from the 59
splice site in intron 2 and A.T In5, an A to T 34 bp from the 39
splice site in intron 5. The four mutations in the 39UTR comprised
rs12135247, rs104825, rs11072 and rs1048260. None of these
were located in any of the characterized regulatory sequences [48].
Mutations in the promoter region comprised rs7534480 within the
Neurogenin binding site (NGN1/3) and rs6690434, a highly
conserved residue within the myoblast-determining factor
(MYOD), the positions given are according to [49].
Non-synonymous and nonsense mutations with the exception of
F364L, reported here for the first time, have previously been
characterized with specific focus on familial and sporadic prostate
cancer. F364L is located on the border of the protein kinase-like
Figure 1. The entire coding and flanking intron sequences, the 59 and 39 UTR and the promoter region of RNASEL were analyzed for
mutations by direct sequencing of leukocyte DNA from patients with cervix cancer (primers are listed in table 3). The two well-
described exonic SNPs (rs627928 and K724K) are not illustrated. Genotype frequencies of the SNPs determined in the controls are given beneath the
illustration of each SNP, along with a P-value of the marginal effect of the SNP. The Bonferroni corrected significance level is 0.05/12=0.004. The
genotype frequencies of the cases in the remaining 3 SNPs are: rs627928–7:20:13 (G/G:G/T:T/T); A-T In5–26:13:0 (A/A:A/T:T/T) and K724K–37:3:0 (A/
A:A/G:G/G). The ideogram color code is defined as: white, coding region; grey, UTR; black, intragenic regions.
doi:10.1371/journal.pone.0002492.g001
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has yet been established. One patient was heterozygous for F364L,
whereas none was found among 407 controls in the current study.
None of the cervix cancer patients were homozygous for any of
the rare alleles of the intronic mutations (Figure 1). It is not known
whether any of these mutations affect the translation or the
splicing efficiency.
We established the genotype frequencies of twelve out of the
fifteen mutations found in RNASEL in a Danish control population
(n=502) using the primer extension method. The number of
successfully genotyped controls varies according to the specific
mutation (Figure 1).
Comparison of genotype frequencies in different cohorts
The genotype frequencies were compared between the cervix
cancer patients and the controls using Fisher’s exact test (Figure 1).
The frequencies of SNP rs3738579 were found to differ most in the
two groups (P-value: 0.086), but none of the SNPs showed significant
differences. Subsequently, we investigated three SNPs in 199 Danish
patients diagnosed with primary unilateral breast cancer and in 382
Danish HNSCC patients. SNP rs3738579 was chosen because it
showed the most deviating frequencies; SNP R462Q because it is
knowntoaffectthe RNaseLactivity,wherethegenotypesGAorAA
are associated with a decrease in RNase L activity, reduced ability to
clear viral infections, linked to familial prostate cancer, and to more
advanced disease in pancreatic cancer [13,27]; SNP rs6690434,
which is located in the promoter region of RNASEL affecting a
potential MyoD binding site, could be of possible regulatory
importance. RNase L has been found to regulate MyoD mRNA
stability and to be involved in myoblast differentiation [50].
Random samples were sequenced to verify the genotypes,
established by the primer extension method, of each SNP
(rs3738579, SNP R462Q and rs6690434). In total, samples from
all cervix cancer patients, 47% (239/504) controls, 34% (62/185)
breast cancer patients and 13% (47/375) HNSCC patients were
sequenced to verify the interpretation of the genotypes.
The implication of the 59UTR SNP rs3738579 in viral and
non-viral induced cancer
The genotype frequencies for each sample of cancer patients
(breast and HNSCC) were compared to the controls. A significant
difference was seen only for rs3738579 in breast cancer, P-
value=0.0012 and in HNSCC, P-value=0.0006.
We found that the genotype frequencies for rs3738579 were
similar in our control population and the HapMap European
(CEU) population [51], as opposed to the genotype frequencies in
the three similar cancer cohorts (see Table 1). Interestingly, a
combination of data from all three cancer forms provided strong
statistical evidence for rs3738579 as a cancer marker (P-value:
4.43610
25). This finding points to RNASEL as a general marker
for cancer risk being not exclusively linked to viral induced cancer
forms. In addition, heterozygous individuals were overrepresented
in the controls, implying a heterozygote advantage and potential
protection against the three cancer forms.
Considering pairs of SNPs, none of the pairs show an association
with any of the three types of cancer, or all jointly, stronger than the
marginal association with rs3738579, indicating that rs3738579 is a
better marker than any combination of two SNPs.
Table 2 shows odds ratios (ODs) for the three different
genotypes of rs3738579; overall the ODs are similar for the three
types of cancer.
Linkage disequilibrium (LD) across RNASEL
To our knowledge the implication of rs3738579 on activity or
expression of RNase L is unknown. The mutation is not located within
a uORF (un-translated open reading frame) but may change the
conformation of the mRNA. One explanation could be that
rs3738579 is in linkage disequilibrium (LD) with a not yet identified
mutation in the regulatory regions of RNASEL or a causative mutation
in a nearby gene within the same haploblock (see Figure 2). The LD
pattern across the sequenced region for the control population was
calculated. Two independent LD blocks were found, one in the
39UTR region and one in the region spanning the promoter region
and exon 2. If a causative mutation exists, being in LD with
rs3738579, it can only be present upstream from the introns flanking
exon 2, since all exons, flanking intron and promoter sequences have
been directly sequenced in all 42 cervical cancer patients.
A heterozygous advantage was found in the study linking
infection by a novel gammaretrovirus (XMLV) to the R462Q
genotypes. Here, 40% of the analyzed prostate cancer patients,
being homozygous for the Q allele, and 1.9% of the patients being
homozygous for the R allele, were infected by XMLV. None of the
analyzed heterozygous patients carried the infection [30]. This
mutation is in LD with rs3738579, where the heterozygous
Table 1. Genotype frequencies for SNP rs3738579
Genotype Control population HapMap data Cervix cancer patients Breast cancer patients HNSCC patients
CC 45 (0.108) 7 (0.117) 3 (0.071) 34 (0.184) 54 (0.144)
CT 228 (0.545) 33 (0.550) 17 (0.405) 73 (0.395) 153 (0.408)
TT 145 (0.347) 20 (0.333) 22 (0.524) 78 (0.422) 168 (0.448)
The genotype frequencies are given for controls, n=502, the CEU HapMap population, n=60 cervix cancer, n=42, breast cancer, n=199 and HNSCC, n=382,
respectively, and the proportion of individuals with the genotype is given as percent in brackets. The genotype frequencies of the controls and the HapMap population
are similar (P-value: 0.95), and the genotype frequencies of the three cancer populations are similar (P-value for cervix and breast: 0.18; cervix and head and neck: 0.41;
breast and head and neck: 0.48).
doi:10.1371/journal.pone.0002492.t001
Table 2. Odds Ratio for the SNP rs3738579 in the three cancer
samples and in the samples combined, compared to the
control population.
Genotype:
rs3738579
Cervix
Cancer:
Head and Neck
Cancer (HNSCC):
Breast
Cancer: Total:
CC 0.638 1.394 1.866 1.476
CT 0.567 0.574 0.543 0.564
TT 2.071 1.528 1.372 1.511
doi:10.1371/journal.pone.0002492.t002
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rare and frequent alleles, respectively.
Establishment of the HPV genotype
The HPV genotype was established in DNA isolated from
cervical carcinomas using the Linear Array HPV Genotyping Test
kit (Roche Diagnostics GmbH, Mannheim, Germany), which
allow for detection of 37 different HPV genotypes including 13
from the high-risk group. We found no correlation between HPV
strains and rs3738579 genotypes. All cervical tumor samples were
infected with HPV16 and in addition 52% with HPV18, in total
eleven different HPV strains were identified in the 42 cervix
patients (Figure 3). In comparison, HNSCC is a highly
heterogeneous disease with predominantly squamous cell carcino-
mas and only 30% of the study sample was expected to carry an
HPV infection. This strengthens the hypothesis presented here
that RNase L may be a general marker for cancer risk and not
specifically linked to viral induced cancers.
Conclusion
A heterozygote advantage and protective potential of RNASEL
have not previously been reported. SNP rs3738579 is located
within the 59UTR region and may be implicated in posttran-
scriptional regulation or a mediator of an existing low penetrant
mutation. One such mutation could be the R462Q located within
the same exon. 462Q decreases the activity of RNase L up to three
fold and has been intensively studied in large prostate cancer
Figure 2. Linkage Disequilibrium (LD)-plot of the region containing RNASEL. Each square indicates the level of LD between two SNPs. The
color code is defined as: red (high LD), LOD(2 and D9=1; shades of pink/red, LOD(2 and D9,1; blue, LOD,2 and D9=1; white, LOD,2 and D9,1. The
top of the figure shows the genomic position and the known genes in the region (yellow: exon; grey: UTR; black line: intron) [54]. Note that exon 1 is
not shown. The two SNPs within the promoter are illustrated to the far right.
doi:10.1371/journal.pone.0002492.g002
Figure 3. Distribution of HPV genotypes in cervical carcinomas.
Thirty-two uterine cervix tumors were infected by more than one HPV
strain and all 42 cases were infected by the high-risk HPV16.
doi:10.1371/journal.pone.0002492.g003
RNASEL Predicts Cancer Risk
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rs3738579 may help explain these diverse results.
Interestingly, the implication of a mutated RNASEL on viral
induced cervical cancer has not been described before, despite the
well-documented role of the enzyme in the degradation of viral
RNA. Furthermore, characterization of the new 59UTR mutation
rs3738579 in patients with sporadic breast and HNSCC led to the
hypothesis that RNase L is a general marker for cancer risk, not
restricted to familial prostate cancer.
Materials and Methods
Cervix cancer patients
Pre-treatment buffy coat blood samples, (n=40) and tumor
tissue samples, (n=42) were collected from patients with newly
diagnosed carcinoma of the uterine cervix. Median age was 59
(range 28–84). Twenty-nine women were postmenopausal, 12
premenopausal. Nineteen women were current tobacco smokers
and smoking history was not available in five cases. Tumors were
FIGO stage IB, n=4; IIA, n=1; IIB, n=20; IIIa, n=2 and IIIIB,
n=15. The majority of tumors were squamous cell carcinoma,
n=37 while one was an adenocarcinoma, one mixed adeno/
neuroendocrine and 3 were adenosquamous carcinoma.
DNA preparation from fresh frozen cervix cancer tissue
for HPV analysis
DNA was isolated from 42 fresh frozen tumor tissues according
to the manufacturers’ recommendations for the Linear Array HPV
Genotyping Test kit (Roche Diagnostics GmbH, Mannheim,
Germany). In brief, the tissue was dissolved in 250 ml PBS, 80 ml
tissue lysis buffer (ALT) and 20 ml Proteinase K, mixed/vortexed
briefly and incubated for 60 min at 56uC. 250 ml lysis buffer (AL)
containing carrier RNA was added, mixed and incubated at 70uC
for 30 min. 300 ml 96% ethanol was added, the solutions were
mixed thoroughly and incubated for 5 min at room temperature.
The tubes were briefly centrifuged and all liquid transferred to a
QlAamp column, the lysate was removed by a vacuum pump, 750
ml wash buffer (AW2) was added and left for 1 min. The wash
buffer was removed and the samples washed with 750 ml 96%
ethanol. The filter from the column was transferred to a new tube.
120 ml elution buffer was added and collected by centrifugation
after 2 min incubation at room temperature.
The samples can be stored at 2–8uC for 7 days or at 20uC for 8
weeks.
DNA was purified according to standard procedures.
Control population
DNA was extracted from peripheral blood according to a
modified salt precipitation method from 502 Danish medical
Table 3. Primer sequences for DNA sequencing and SNP
genotype assessment
Polymorphism
Oligonucleotide
name Oligonucleotide sequence 59-39
rs7534480 SNPrs7534480 GGTGATGGTGCCATCTGT
RNASELPrr GTCTCCAAAGCCCAAGAATTC
RNASELPrf GATGGTGGGTCAATGATGC
rs6690434 SNPrs6690434 GTGAGTTGAGTGAGCTGAGA
RNASELPrr GTCTCCAAAGCCCAAGAATTC
RNASELPrf GATGGTGGGTCAATGATGC
rs2274509 SNPrs2274509 CTGGAGGAAAGCAATAGCC
RNASELPrr GTCTCCAAAGCCCAAGAATTC
RNASELPrf GATGGTGGGTCAATGATGC
rs3738579 SNPT73C GTTGCCAGAGAATCCCCAA
RNASEL2ar2 CTCATTGACATCTGCTC
RNASEL2prf2 GATTCAAGTGTTTTCTCCC
I97L SNPI97L GCAATCGCTGCGAGGA
RNASEL2ar2 CTCATTGACATCTGCTC
RNASEL2af TGCATTTTCTCAAGGAAAAGGC
E265X SNPE265X CTGGAGCAAGAGCACATA
RNASEL2br GAGGGTGAAAATCTTCTTTGGC
RNASEL2bf3 AGTGGAGAAGAAGCACTTGG
F364L SNPF364L GATTGGCAAACTCAAGTTC
RNASEL2cr2 CTCTAGGCCTTTCCTCTC
RNASEL2cf GGATCTTGTTATGACAGCG
rs486907 SNPR462Q: AAATATAGATGACAGGACATTT
RNASEL2cr CTCTAGGCCTTTCCTCTC
RNASEL2cf2: CAGTCACTTGGTGACATTC
rs627928 SNPD541E: GAAGCATCTCATTTGAGGA
RNASEL4r CCCTTTCCATCCTGGAGG
RNASEL CATCTTTGGCTTGATTTATGG
AGIntron2 SNPAGIn2: GGGATCTTTGTTTATGATAGG
RNASELIn2r: GAACCCAGTTATAATTGGTAG
RNASEL2cf2: CAGTCACTTGGTGACATTC
rs516134 SNPrs516134 GGAA AGGCTGTTCT TGCCT
rs516134r GCACAGATTTGTAAAGGAC
rs516134f GAGGTCTAAGTGCAATGATG
rs533259 SNPrs533259 CTTGATGCCATCACAGCTTC
rs533259r CTGACTGTCCAGCATGAG
rs533259f GAACCAGTAAGGGGTGC
ATIn5 SNPATIn5: CTAAATGATCTAAATGATCATGA
RNASEL5r GACTAACCCCTGCACTATAGG
RNASEL5f GGAAAGGGAGGGATGGGATG
rs11807829 SNPK724K CAGCTCCATCACACTGAGG
RNASEL7r CTCTACAGCTAATAAGTAGTTC
RNASEL7f CAAGCATGCTGAACAATTTGTG
rs12135247 SNPrs12135247 GTATAAGTCTGGGCACTGG
RNASEL39UTRr TGTACGAAGATGGTTCATTC
RNASEL39UTRf CTGGTGATCTATGTCTACAC
A857C, 39UTR SNPrs104825 GCTGAGGTTGAGAAAACCUG
RNASEL39UTRr TGTACGAAGATGGTTCATTC
RNASEL39UTRf CTGGTGATCTATGTCTACAC
Polymorphism
Oligonucleotide
name Oligonucleotide sequence 59-39
rs11072 SNPrs11072 GTCTGCCAAGTGGGAATGTT
RNASEL39UTRr TGTACGAAGATGGTTCATTC
RNASEL39UTRf CTGGTGATCTATGTCTACAC
rs1048260 SNPrs1048260 GGTGCTCATTACAAATCAGA
rs1048260r CAGAAACTCTCAGAGAATTC
rs1048260f CTTCCCATACCCAGTCTA
doi:10.1371/journal.pone.0002492.t003
Table 3. cont.
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The Local Ethical Committee, Aarhus County, Denmark,
approved the current study. All individuals were informed and
consented both verbally and in writing.
Breast cancer patients
Matching blood and tumor samples were collected from 199
primary breast cancer patients. All patients had primary unilateral
breast carcinoma without evidence of disseminated disease, no
other malignancies. Complete clinical, histopatological and
biological information were available, the cohort is described in
[53]. Purification of DNA was carried out using a modified salt
precipitation protocol as described in [52].
Head and Neck cancer patients
DNA was derived from fibroblast cultures obtained from 382
consecutive patients with HNSCC treated at the Aarhus
University Hospital. The patients were treated with primary
radiotherapy according to the protocols and guidelines from the
Danish Head and Neck Cancer Group (http://www.dahanca.dk/).
The primary tumor sites were larynx, oropharynx, hypopharynx,
nasopharynx and oral cavity.
Ethical approval
The Local Ethical Committee, Aarhus County, Denmark,
approved the current study. All patients were informed and
consented both verbally and in writing.
Mutation analysis
Both strands of all DNA fragments were sequenced. Primer
sequences and PCR conditions are listed in table 3. The initial
standard PCR amplification comprised 20 ng DNA, 1 pmol of each
primer, 250 mMd N T P( R o c h e ) ,1 6buffer (supplied with the enzyme)
and 0.5 unit Taq polymerase (Roche) in a final volume of 25 ml.
PCR cycle conditions were as follows: 1 cycle of 94uCf o r4m i n ,
35 cycles of 93uC for 35 sec, 59uC for 40 sec, 72uCf o r1m i n
followed by 72uC for 10 min. Products were analyzed by
electrophoresis in a 1% agarose gel stained with ethidium bromide.
Generation of a single stranded product for sequencing comprised: 2
ml PCR product from above, 5 pmol primer, 6 mlo fa2 . 5 6buffer
(supplied with the BigDye kit, ABI, Foster City, CA) and 2 ml
Reaction mix (BigDye ver. 2.0 and 1.1; ABI, Foster City, CA)
supplied with ddH2O to a final volume of 20 ml. Conditions for cycle
sequencing were as follows: 1 cycle of 96uCf o r5m i n ,2 5c y c l e so f
96uC for 30 sec, 59uC for 15 sec, 60uCf o r4m i n .T h ep r o d u c t s
were separated by capillary electrophoresis (ABI 3100, Applied
Biosystems, Foster City, CA) and evaluated using the software
Sequencing analysisH (Applied Biosystems, Foster City, CA).
Single nucleotide polymorphism (SNP) detection
The primer sequences for PCR amplification of the target
region containing one or additional SNPs, and for detecting the
individual SNP are listed in Table 3.
The PCR amplification comprised: 20 ng DNA, 200 mM
dNTP, 0.4 Units Taq polymerase (Ampliqon, Bie and Berntsen,
DK), 16buffer supplied with the enzyme and additional 1.6 mM
MgCl2 in a final volume of 15 ml. Depending on the DNA
fragment the annealing temperature was ranging between 54–
60uC. The genotypes were determined by single nucleotide
extension using the SNaPshotH kit following the manufacturers’
instructions (Applied Biosystems, Foster City, CA). All products
were detected via capillary electrophoresis using the software
GeneMapperH (ABI 3100, Biosystems Solutions, Foster City, CA).
HPV detection
The Linear Array HPV Genotyping Test kit (Roche Diagnostics
GmbH, Mannheim, Germany) allows for detection of 37 different
HPV genotypes including 13 from the high-risk group. The
differentiation between HPV genotypes is based upon PCR
amplification of the highly polymorphic L1 region followed by
hybridization to specific oligonucleotide probes and colorimetric
detection. The manufacturers’ guidelines were followed.
Statistical methods
A Bonferroni corrected Fisher’s exact test is used for all tests.
For cervical cancer 12 tests are for single marker associations,
yielding a Bonferroni corrected significance level of 0.05/
12=0.004, and 66 tests are made for SNP-pair associations
yielding a corrected level of 0.05/66=0.0008. For breast cancer
and HNSCC 3 tests are made for single marker associations,
yielding a Bonferroni corrected significance level of 0.05/
3=0.0167, and 3 tests are made for SNP-pair associations.
Missing data are handled by omitting individuals with missing
data in the genotype counts; e.g. all individuals with missing data
in either rs3738579 or R462Q are omitted when calculating the
genotype frequencies of that specific SNP-pair.
ODs are calculated as p(12q)/[(12p)q] where p is the frequency
of one of the three genotypes in the cancer samples (cervix, head
and neck, breast, or combined) and q the frequency of the
genotype in the control population.
HapMap population
The genotype frequencies for SNP rs3738579 in the European
HapMap population are found by using the CEU population in
the HapMap genome browser with HapMap data rel21a on NCBI
build 35. [51]
Linkage disequilibrium
Linkage disequilibrium (LD) is investigated by the program
HaploView (v. 3.31) using genome build NCBI35 [54]. Only
polymorphic SNPs are shown in Figure 2.
Acknowledgments
T. Kjeldsen and E.L. Hein are greatly acknowledged for their excellent
technical assistance.
Author Contributions
Conceived and designed the experiments: CW LH ER MB KD. Performed
the experiments: BM ER MB KD. Analyzed the data: CW BM LH ER
MB KD. Contributed reagents/materials/analysis tools: JO LH MN.
Wrote the paper: LH. Other: Contributed to the manuscript: CW BM.
References
1. Zhou A, Hassel BA, Silverman RH (1993) Expression cloning of 2-5A-
dependent RNAase: a uniquely regulated mediator of interferon action. Cell 72:
753–765.
2. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH (1993) A dominant
negative mutant of 2-5A-dependent RNase suppresses antiproliferative and
antiviral effects of interferon. Embo J 12: 3297–3304.
3. Xiang Y, Wang Z, Murakami J, Plummer S, Klein EA, et al. (2003) Effects of
RNase L mutations associated with prostate cancer on apoptosis induced by
29,59-oligoadenylates. Cancer Res 63: 6795–6801.
4. Rusch L, Zhou A, Silverman RH (2000) Caspase-dependent apoptosis by 29,59-
oligoadenylate activation of RNase L is enhanced by IFN-beta. J Interferon
Cytokine Res 20: 1091–1100.
RNASEL Predicts Cancer Risk
PLoS ONE | www.plosone.org 7 June 2008 | Volume 3 | Issue 6 | e24925. Roy FL, Salehzada T, Bisbal C, Dougherty JP, Peltz SW (2005) A newly
discovered function for RNase L in regulating translation termination. Nat
Struct Mol Biol 12: 505–512.
6. Hovanessian AG, Brown RE, Kerr IM (1977) Synthesis of low molecular weight
inhibitor of protein synthesis with enzyme from interferon-treated cells. Nature
268: 537–540.
7. Kerr IM, Brown RE (1978) pppA29p59A29p59A: an inhibitor of protein synthesis
synthesized with an enzyme fraction from interferon-treated cells. Proc Natl
Acad Sci U S A 75: 256–260.
8. Naik S, Paranjape JM, Silverman RH (1998) RNase L dimerization in a
mammalian two-hybrid system in response to 29,59-oligoadenylates. Nucleic
Acids Res 26: 1522–1527.
9. Dong B, Niwa M, Walter P, Silverman RH (2001) Basis for regulated RNA
cleavage by functional analysis of RNase L and Ire1p. Rna 7: 361–373.
10. Tanaka N, Nakanishi M, Kusakabe Y, Goto Y, Kitade Y, et al. (2004) Structural
basis for recognition of 29,59-linked oligoadenylates by human ribonuclease L.
Embo J 23: 3929–3938.
11. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The
protein kinase complement of the human genome. Science 298: 1912–1934.
12. Dong B, Silverman RH (1999) Alternative function of a protein kinase homology
domain in 29,5 9-oligoadenylate dependent RNase L. Nucleic Acids Res 27:
439–445.
13. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, et al. (2002)
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer
cases. Nat Genet 32: 581–583.
14. Liu CY, Wong HN, Schauerte JA, Kaufman RJ (2002) The protein kinase/
endoribonuclease IRE1alpha that signals the unfolded protein response has a
luminal N-terminal ligand-independent dimerization domain. J Biol Chem 277:
18346–18356.
15. Patmore HS, Ashman JN, Cawkwell L, MacDonald A, Stafford ND, et al. (2004)
Can a genetic signature for metastatic head and neck squamous cell carcinoma
be characterised by comparative genomic hybridisation? Br J Cancer 90:
1976–1982.
16. Halder A, Halder S, Fauzdar A (2005) A preliminary investigation of genomic
screening in cervical carcinoma by comparative genomic hybridization.
Indian J Med Res 122: 434–446.
17. Hoglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F (2002) Multivariate
analysis of chromosomal imbalances in breast cancer delineates cytogenetic
pathways and reveals complex relationships among imbalances. Cancer Res 62:
2675–2680.
18. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, et al. (2002) Germline
mutations in the ribonuclease L gene in families showing linkage with HPC1.
Nat Genet 30: 181–184.
19. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, et al. (2002)
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in
patients and families with prostate cancer. Am J Hum Genet 70: 1299–1304.
20. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, et al. (2002) A
novel founder mutation in the RNASEL gene, 471delAAAG, is associated with
prostate cancer in Ashkenazi Jews. Am J Hum Genet 71: 981–984.
21. Li H, Tai BC (2006) RNASEL gene polymorphisms and the risk of prostate
cancer: a meta-analysis. Clin Cancer Res 12: 5713–5719.
22. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, et al. (2003) Role of
genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a
Japanese population. Br J Cancer 89: 691–696.
23. Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, et al. (2004)
Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic
prostate cancer. Clin Cancer Res 10: 7150–7156.
24. Wang L, McDonnell SK, Elkins DA, Slager SL, Christensen E, et al. (2002)
Analysis of the RNASEL gene in familial and sporadic prostate cancer.
Am J Hum Genet 71: 116–123.
25. Maier C, Haeusler J, Herkommer K, Vesovic Z, Hoegel J, et al. (2005) Mutation
screening and association study of RNASEL as a prostate cancer susceptibility
gene. Br J Cancer 92: 1159–1164.
26. Rennert H, Zeigler-Johnson CM, Addya K, Finley MJ, Walker AH, et al. (2005)
Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and
MSR1 with prostate cancer severity in European American and African
American men. Cancer Epidemiol Biomarkers Prev 14: 949–957.
27. Bartsch DK, Fendrich V, Slater EP, Sina-Frey M, Rieder H, et al. (2005)
RNASEL germline variants are associated with pancreatic cancer. Int J Cancer
117: 718–722.
28. Kruger S, Silber AS, Engel C, Gorgens H, Mangold E, et al. (2005) Arg462Gln
sequence variation in the prostate-cancer-susceptibility gene RNASEL and age
of onset of hereditary non-polyposis colorectal cancer: a case-control study.
Lancet Oncol 6: 566–572.
29. Sevinc A, Yannoukakos D, Konstantopoulou I, Manguoglu E, Luleci G, et al.
(2004) Lack of association between RNASEL Arg462Gln variant and the risk of
breast cancer. Anticancer Res 24: 2547–2549.
30. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, et al. (2006)
Identification of a novel Gammaretrovirus in prostate tumors of patients
homozygous for R462Q RNASEL variant. PLoS Pathog 2: e25.
31. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
32. Ragin CC, Taioli E (2007) Survival of squamous cell carcinoma of the head and
neck in relation to human papillomavirus infection: review and meta-analysis.
Int J Cancer 121: 1813–1820.
33. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence,
mortality, and prevalence across five continents: defining priorities to reduce
cancer disparities in different geographic regions of the world. J Clin Oncol 24:
2137–2150.
34. Lilienfeld AM, Johnson EA (1955) The age distribution in female breast and
genital cancers. Cancer 8: 875–882.
35. Henderson BE, Feigelson HS (2000) Hormonal carcinogenesis. Carcinogenesis
21: 427–433.
36. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical
application. Nat Rev Cancer 2: 342–350.
37. Kreimer AR, Clifford GM, Boyle P, Franceschi S (2005) Human papillomavirus
types in head and neck squamous cell carcinomas worldwide: a systematic
review. Cancer Epidemiol Biomarkers Prev 14: 467–475.
38. Hobbs CG, Sterne JA, Bailey M, Heyderman RS, Birchall MA, et al. (2006)
Human papillomavirus and head and neck cancer: a systematic review and
meta-analysis. Clin Otolaryngol 31: 259–266.
39. An HJ, Kim KR, Kim IS, Kim DW, Park MH, et al. (2004) Prevalence of
human papillomavirus DNA in various histological subtypes of cervical
adenocarcinoma: a population-based study. Mod Pathol.
40. Kubbutat MH, Vousden KH (1998) New HPV E6 binding proteins: dangerous
liaisons? Trends Microbiol 6: 173–175.
41. Thomas M, Matlashewski G, Pim D, Banks L (1996) Induction of apoptosis by
p53 is independent of its oligomeric state and can be abolished by HPV-18 E6
through ubiquitin mediated degradation. Oncogene 13: 265–273.
42. Di Lonardo A, Venuti A, Marcante ML (1992) Human papillomavirus in breast
cancer. Breast Cancer Res Treat 21: 95–100.
43. Choi YL, Cho EY, Kim JH, Nam SJ, Oh YL, et al. (2008) Detection of Human
Papillomavirus DNA by DNA Chip in Breast Carcinomas of Korean Women.
Tumour Biol 28: 327–332.
44. Theodorou V, Kimm MA, Boer M, Wessels L, Theelen W, et al. (2007) MMTV
insertional mutagenesis identifies genes, gene families and pathways involved in
mammary cancer. Nat Genet 39: 759–769.
45. Lawson JS, Gunzburg WH, Whitaker NJ (2006) Viruses and human breast
cancer. Future Microbiol 1: 33–51.
46. Silverman RH (2003) Implications for RNase L in prostate cancer biology.
Biochemistry 42: 1805–1812.
47. Liang SL, Quirk D, Zhou A (2006) RNase L: its biological roles and regulation.
IUBMB Life 58: 508–514.
48. Li XL, Andersen JB, Ezelle HJ, Wilson GM, Hassel BA (2007) Post-
transcriptional regulation of RNase-L expression is mediated by the 39-
untranslated region of its mRNA. J Biol Chem 282: 7950–7960.
49. Zhou A, Molinaro RJ, Malathi K, Silverman RH (2005) Mapping of the human
RNASEL promoter and expression in cancer and normal cells. J Interferon
Cytokine Res 25: 595–603.
50. Bisbal C, Silhol M, Laubenthal H, Kaluza T, Carnac G, et al. (2000) The 29-59
oligoadenylate/RNase L/RNase L inhibitor pathway regulates both MyoD
mRNA stability and muscle cell differentiation. Mol Cell Biol 20: 4959–4969.
51. (2003) The International HapMap Project. Nature 426: 789–796.
52. Hansen LL, Andersen J, Overgaard J, Kruse TA (1998) Molecular genetic
analysis of easily accessible breast tumour DNA, purified from the leftover from
hormone receptor measurement. APMIS 106: 371–377.
53. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA (1998) Allelic loss of
16q23.2–24.2 is an independent marker of good prognosis in primary breast
cancer. Cancer Res 58: 2166–2169.
54. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
RNASEL Predicts Cancer Risk
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2492